Peijia Medical Ltd. (4WO) Stock Price & Analysis
4WO Stock Chart & Stats
- Day’s Range
- EUR 0.39 - EUR 0.39
- 52-Week Range
- EUR 0.38 - EUR 0.78
- Previous Close
- EUR 0.38
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 286.41M
- Enterprise Value
- EUR 2.46B
- Total Cash (Recent Filing)
- EUR 761.12M
- Total Debt (Recent Filing)
- EUR 652.57M
- Price to Earnings (P/E)
- ―
- Beta
- 0.71
- Next Earnings
- Apr 01, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Scale And Gross Margin
Meaningful revenue scale and a strong gross margin indicate that Peijia has established commercial demand and retains substantial value from each sale. If growth continues, this gross-profit base can support operating leverage and investment in further cardiovascular and neurovascular product expansion.
Manageable Leverage
Low leverage gives Peijia more financial flexibility than a highly indebted device company and limits the immediate burden of interest and refinancing. A sizable equity base can provide greater resilience while management works to convert product development and commercial scale into sustainable profitability.
Narrowing Losses
The narrowing of losses alongside substantial historical revenue expansion suggests that Peijia is moving toward better operating leverage, even though it has not reached profitability. Continued improvement could strengthen earnings quality as the existing commercial platform absorbs more revenue and fixed costs.
Bears Say
Persistent Operating Losses
Persistent operating and net losses show that Peijia’s current revenue base does not yet cover its full cost structure. Until profitability is established, the company remains exposed to execution risk and may have less ability to fund product development, commercialization, and expansion from internally generated earnings.
Negative Cash Generation
Ongoing negative operating and free cash flow means accounting revenue and gross profit are not yet translating into financial resources. Continued cash consumption can constrain investment flexibility and increase reliance on external funding until Peijia improves profitability and cash conversion.
Negative Returns On Equity
Negative ROE indicates that the company is currently destroying rather than compounding value on its equity base. If losses persist, accumulated deficits could gradually reduce capital strength and limit the resources available to support long-term product development and commercial growth.
Peijia Medical Ltd. News
4WO FAQ
What was Peijia Medical Ltd.’s price range in the past 12 months?
What is Peijia Medical Ltd.’s market cap?
When is Peijia Medical Ltd.’s upcoming earnings report date?
How were Peijia Medical Ltd.’s earnings last quarter?
Is Peijia Medical Ltd. overvalued?
Does Peijia Medical Ltd. pay dividends?
What is Peijia Medical Ltd.’s EPS estimate?
How many shares outstanding does Peijia Medical Ltd. have?
What happened to Peijia Medical Ltd.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Peijia Medical Ltd.?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Peijia Medical Ltd.
Peijia Medical Limited specializes in the innovation and development of advanced medical devices for transcatheter valve therapies and neurointerventional procedures. Their extensive portfolio of transcatheter valve solutions includes numerous TAVR (transcatheter aortic valve replacement) systems, such as TaurusOne, the retrievable TaurusElite, TaurusNXT (a non-glutaraldehyde dry-tissue system), TaurusApex (featuring polymer leaflets), and Trilogy. For mitral valve interventions, they offer the HighLife transseptal replacement system, SpyderOne (a transapical TMVR system), Sutra for coaptation augmentation, and the GeminiOne edge-to-edge repair system. They also provide the MonarQ and Peijia systems for transcatheter tricuspid valve replacement. Complementary devices supporting these procedures include the TaurusAtlas transfemoral balloon catheter, TaurusExplora pre-shaped guidewire, and introducer sheaths. In the neurointerventional field, Peijia Medical develops devices like the Jasper and Presgo detachable coils (including the Jasper SS variant), various intracranial adjunctive stents such as NeuroStellar, and the SacSpeed balloon dilatation catheter. Additional offerings comprise the Tethys AS aspiration catheter, Syphonet stent retriever, Neway balloon microcatheter, Fluxcap balloon guiding catheter, Presgo microcatheters and micro guidewires, Heralder guiding and distal access catheters, the Tethys intermediate catheter, and the Jasper power supply. Furthermore, the company engages in trading activities. Peijia Medical Limited was founded in 2012 and is headquartered in Suzhou, People's Republic of China.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Yi Zhang
- Employees
- 1,033
- Website
- www.peijiamedical.com
- Address
- No.18 Yangjiatian Road, Suzhou, JS, 215028, CN
Peijia Medical Ltd. (4WO) Earnings & Revenues
4WO Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 1 | 15 |
| Technical Analysis | 6 | 1 | 3 |
| Moving Averages | 0 | 0 | 12 |
